Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone

Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant re...

Full description

Saved in:
Bibliographic Details
Main Authors: Satriyo Dwi Suryantoro, -, Mochammad Thaha, -, Pranawa, -, Djoko Santoso, -, Nunuk Mardiana, -, Widodo, -, Aditiawardana, -, Artaria Tjempakasari, -, Ardityo Rahmat Ardhany, -, Dana Pramudya, -, Decsa Medika Hertanto, -, Evy Febriane, -, Meryana, -, Maria Angela, -, Ari Christy Muliono, -, Handoko Tanuwidjaja, -, Philia Setiawan, -, David Sugiarto, -
Format: Article PeerReviewed
Language:English
English
English
English
Published: Open Learning on Enteric Pathogens 2021
Subjects:
R Medicine (General)
RC Internal medicine
Online Access:https://repository.unair.ac.id/112604/1/02.%20Severe%20COVID-19%20infection%20in%20a%20kidney%20transplant%20recipient%20treated%20with.pdf
https://repository.unair.ac.id/112604/2/JIDC%20-%20Kidney%20Transplant.pdf
https://repository.unair.ac.id/112604/3/2.pdf
https://repository.unair.ac.id/112604/4/Severe%20COVID-19%20infection%20in%20a%20kidney%20transplant%20recipient%20treated%20with%20lopinavir_ritonavir%2C%20hydroxychloroquine%20and%20dexamethasone.pdf
https://repository.unair.ac.id/112604/
https://jidc.org/index.php/journal/article/view/34669593
https://doi.org/10.3855/jidc.14952
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 – whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient’s condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.

Similar Items